- Conditions
- Tachycardia, Chronic Orthostatic Intolerance
- Interventions
- Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
- Drug · Other · Dietary Supplement + 3 more
- Lead sponsor
- Satish R. Raj
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 415
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure, Congestive Heart Failure
- Interventions
- Isosorbide Dinitrate, Isosorbide Dinitrate + Hydralazine, Placebo
- Drug
- Lead sponsor
- Corporal Michael J. Crescenz VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alcohol Use Disorder
- Interventions
- ANS-6637 Low Dose, ANS-6637 High Dose, Matched Placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 21 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alcoholism, Sleep Initiation and Maintenance Disorders
- Interventions
- Quetiapine XR, Placebo.
- Drug
- Lead sponsor
- Subhajit Chakravorty
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bipolar Disorder, Alcohol Abuse/Dependence
- Interventions
- Quetiapine
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Primary Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert
- Drug · Device
- Lead sponsor
- ForSight Vision5, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 10
- States / cities
- Artesia, California • La Jolla, California • Newport Beach, California + 7 more
- Conditions
- Chronic Migraine
- Interventions
- propranolol LA, topiramate, placebo
- Drug
- Lead sponsor
- Anne Lindblad
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tuscon, Arizona • Chico, California + 35 more
- Conditions
- Opioid Pain Medication
- Interventions
- Tranexamic acid, Aminocaproic acid, Recombinant Human Thrombin, Lidocaine Hydrochloride with Epinephrine, Bupivacaine Hydrochloride with Epinephrine
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alcohol Consumption
- Interventions
- Placebo, 10 mg Obeticholic Acid (OCA)
- Drug
- Lead sponsor
- Suthat Liangpunsakul
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Spinal Cord Injury, Respiratory Muscle Weakness
- Interventions
- Oral Albuterol Extended Release, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Vitamin D Deficiency, Polytrauma, Orthopedic Disorder
- Interventions
- Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL], Propylene Glycol
- Drug
- Lead sponsor
- New York City Health and Hospitals Corporation
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Retinopathy of Prematurity (ROP)
- Interventions
- myo-Inositol 5% Injection, Placebo
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 12 Hours to 72 Hours
- Enrollment
- 638 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- Interventions
- umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI
- Drug
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Epilepsy, Dravet Syndrome
- Interventions
- GWP42003-P 5 mg/kg/day Dose, Placebo control, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 4 Years to 10 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 8
- States / cities
- Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Alzheimer's Disease, Depression
- Interventions
- Placebo, Venlafaxine
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • West Reading, Pennsylvania
- Conditions
- Alcohol Use Disorder
- Interventions
- Pioglitazone, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 21 Years to 40 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 707 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 9
- States / cities
- Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 828 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 16
- States / cities
- Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
- Conditions
- Alcohol Related Disorders
- Interventions
- acetaminophen (4g/day), placebo
- Drug
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Healthy Subjects
- Interventions
- Venlafaxine, Moxifloxacin, Drug - placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cocaine Dependence
- Interventions
- Propranolol, Placebo
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Cigarette Smoking
- Interventions
- Propranolol, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Alcohol Dependence, Depression
- Interventions
- Mecamylamine, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
- Interventions
- Fingolimod, Placebo
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas